藥石科技(300725.SZ):商業化訂單整體較為穩定,但會受到單個客户下單時間點的影響
格隆匯8月16日丨藥石科技(300725.SZ)於2023年8月15日上午8:00~9:00進行業績説明會,就“上半年公司GMP項目55個,API項目35個,請問這些項目是如何獲取的?GMP項目的客户都是公司直接和終端客户簽訂的嗎?這裏面有沒有外包單(和海外負責生產API的CDMO簽訂的)?目前商業化訂單的情況?”,公司回覆稱,公司化學能力較強,在應對複雜、不確定因素較多的早期項目中積累了較高的客户聲譽,上述項目大部分都是從早期延伸下來的,少部分是從外部直接導入的。大部分GMP項目在臨牀階段都是終端直接下單,到了商業化階段,終端可能將API生產委託給歐美CDMO,歐美CDMO將重要片段交給藥石來提供。公司商業化訂單整體較為穩定,但會受到單個客户下單時間點的影響,在週期內會有一些波動,商業化訂單是公司主要拓展方向。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.